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The objective of this work was to demonstrate the role of COX-2 enzyme at the vascular in experimental model of metabolic
syndrome. SHR male WKY rats were employed; they were distributed in 8 groups (𝑛 = 8 each): control (W); W + L: WKY
rats receiving 20mg/kg of lumiracoxib by intraesophageal administration; SHR; SHR + L: SHR + 20mg/kg of lumiracoxib by
intraesophageal administration; Fructose-Fed Rats (FFR):WKY rats receiving 10% (w/v) fructose solution in drinking water during
all 12 weeks; FFR + L: FFR + 20mg/kg of lumiracoxib by intraesophageal administration; Fructose-Fed Hypertensive Rats (FFHR):
SHR receiving 10% (w/v) fructose solution in drinking water during all 12 weeks; and FFHR + L: FFHR + 20mg/kg of lumiracoxib
by intraesophageal administration.Metabolic variables, blood pressure,morphometric variables, and oxidative stress variables were
evaluated; alsoMMP-2 andMMP-9 (collagenases), VCAM-1, and NF-𝜅B byWesternblot or IFI were evaluated. FFHR presented all
variables of metabolic syndrome; there was also an increase in oxidative stress variables; vascular remodeling and left ventricular
hypertrophy were evidenced along with a significant increase in the expression of the mentioned proinflammatory molecules and
increased activity and expression of collagenase. Lumiracoxib was able to reverse vascular remodeling changes and inflammation,
demonstrating the involvement of COX-2 in the pathophysiology of vascular remodeling in this experimental model.
1. Introduction
The traditional view of atherosclerosis as a lipid storage
disease falls apart against the large and growing evidence
that inflammation is at the center of all stages of the disease,
from the initial injury until the final stage of thrombotic
complications that compromise blood flow. Advances in the
understanding of vascular inflammation have resulted in a
radical change in the way vascular diseases are approached.
With increased awareness of the active role of the vessel and
its complex interactions with cytokines and immune cells,
this concept unites disorders previously thought be different.
Understanding atherosclerosis as a vascular inflammation
disease is the basis of a new approach for risk stratification
and treatment [1].
Matrix metalloproteinases (MMPs) play an important
role in maintaining homeostasis of extracellular structures.
MMPs are induced by cytokines and by cell-cell and cell-
matrix interactions. Examples of the increased presence of
MMPs in clinical pathology are the SCA, specifically in the
vulnerable region of the plaque [2]. Exposure to oxidized low
density lipoproteins (ox-LDL) or TNF-𝛼 induces the expres-
sion of MT3-MMP, an MMP expressed in the atherosclerotic
plaque of macrophages [3].
C-reactive protein (CRP) presents a rapid and dramatic
response to an inflammatory stimulus. Ultrasensitive C-
reactive protein (hsCRP) has a very important role in
the detection of vascular inflammation and cardiovascular
risk prediction. There is evidence that CRP is involved in
atherosclerosis, especially at its beginning. Proinflammatory
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cytokines production in monocytes and macrophages is
stimulated by PCR [4]. CAMs expression ismediated by CRP,
allowing the increase of leukocyte adhesion and migration
[5–7].
Spontaneously hypertensive rats (SHR) provide a model
of genetic hypertension that allows studying essential hyper-
tension. By administrating carbohydrate diets to rats it is pos-
sible to induce insulin resistance, hyperinsulinemia, dyslipi-
demia, and hypertension. Fructose-Fed-Rats (FFR) provides
a useful experimental model for the study of the interaction
factors shaping metabolic syndrome. This combined model
(FFHR) is representative of hypertensive individuals who
eat a modern Western diet rich in refined sugars. Some
authors postulate this dual model as the most appropriate for
extrapolating results to human models [8, 9].
This experimentalmodel has proved in previous works its
utility for the study of the interaction factors shaping insulin
resistance syndrome [10], including endothelial dysfunction,
the decrease, at the cardiovascular level, of the activity of
the endothelial isoform of nitric oxide synthase (eNOS), and
the increase in the proliferation of vascular smooth muscle
cells [11], and has also provided evidence involving RAS in its
pathophysiology [12].
The objective of this work was to demonstrate that
vascular inflammation and oxidative stress are involved in the
pathophysiologic mechanisms of structural and functional
vascular changes (remodeling) associated to the experimental
model of metabolic syndrome through administration of
lumiracoxib (L) as COX-2 specific anti-inflammatory.
2. Methods
2.1. Animals and Experimental Design. All procedures were
performed according to institutional guidelines for animal
experimentation; protocol was submitted and approved by
the Institutional Committee for Laboratory Animal Use and
Care (CICUAL) of the School of Medicine, UNCuyo. Thirty-
day-old male Wistar Kyoto (WKY) rats and SHR were fed a
standard commercial chow diet ad libitum and housed in a
room under conditions of controlled temperature (20∘C) and
humidity, with a 12-hour light/dark cycle during a 12-week
experimental period. Lumiracoxib (L) was administrated to
respective groups during the last six weeks. Study groups
were divided as follows.
(i) Control (W):WKY receiving food and drinkingwater
(DW) ad libitum;
(ii) SHR: receiving food and DW ad libitum;
(iii) Fructose-Fed Rats (FFR): WKY receiving 10% (w/v)
fructose (Parafarm, Buenos Aires, Argentina) solu-
tion in DW during all 12 weeks;
(iv) Fructose-FedHypertensive Rats (FFHR): SHR receiv-
ing 10% (w/v) fructose solution in DW during all 12
weeks;
(v) FFR + L:FFR receiving 20mg/kg L by intraesophageal
administration;
(vi) FFHR + L:FFHR receiving 20mg/kg L by intrae-
sophageal administration.
At the end of the experimental period, rats were anesthetized
with sodium pentobarbital (50mg/Kg ip), blood samples
were taken, and arteries and organs were aseptically excised
for measurements.
2.2. Systolic Blood Pressure Measurement. Systolic blood
pressure (SBP) was monitored indirectly in conscious pre-
warmed slightly restrained rats by the tail-cuff method and
recorded on a Grass Model 7 polygraph (Grass Instruments
Co., Quincy, MA, USA). The rats were trained in the appara-
tus several times before measurement.
2.3. Biochemical Determinations
2.3.1. HOMA Index and Intraperitoneal Glucose Tolerance
Test. Fasting plasma insulin was assayed by ACS:180SE auto-
mated chemiluminescence system (Bayer, Germany). Plasma
glucose levels were assayed using a commercial colorimet-
ric method (Wiener Lab., Argentina). Homeostasis model
assessment (HOMA) was used as an index to measure the
degree of insulin resistance; it was calculated using the fol-
lowing formula: (insulin (𝜇U/mL) × glucose (mmol/L)/22.5)
[13].
Three days before the end of the experimental period,
a glucose tolerance test (GTT) was performed. Rats fasted
overnight were slightly anesthetized with pentobarbital, and
glucose was administered (2 g/Kg ip). Blood samples were
taken by tail bleeding at 0, 30, 60, and 90 minutes after
injection to determine plasma glucose concentration. The
total area under the curve was calculated as mmol/L/90min.
Assessment of the Lipid Profile. At the end of the experimental
period blood sampleswere drawn from the animals, after fast-
ing for 12 hours. Total plasma cholesterol, HDL-cholesterol,
and triglycerides were assessed using photocolorimetric
enzymatic methods (Wiener Lab., Rosario, Argentina). Data
are expressed in mmol/L.
2.4. Oxidative Stress Determinations
2.4.1. Measurement of Plasma Thiobarbituric Acid-Reactive
Substances (TBARS). In order to demonstrate the effect of
increased oxidative stress at the vascular level, plasma lipid
peroxidation was assessed by TBARS concentration. This
method was based on the reaction between plasma malondi-
aldehyde, a product of lipid peroxidation, and thiobarbituric
acid, as has been previously described [13]. No correction for
sample protein content was necessary because of the nature
of sample [14].
2.5. Measurement of Vascular NAD(P)H-Oxidase Activity.
The lucigenin-derived chemiluminescence assay was used to
determine NAD(P)H-oxidase activity in a segment of tho-
racic aorta, as previously described [14]. To assess NAD(P)H-
oxidase activity, NADPH (500𝜇mol/L) was added, and
chemiluminescence was immediately measured in a liquid
scintillation counter (LKB Wallac Model 1219 Rack-Beta
Scintillation Counter, Finland) set in the out-of-coincidence
Mediators of Inflammation 3
mode. Time-adjusted and normalized-to-tissue-weight scin-
tillation counters were used for calculations. Measurements
were repeated in the absence andpresence of diphenyleneiod-
nium (DPI) (10-6mol/L), which inhibits flavin-containing
enzymes, including NAD(P)H oxidase [15, 16].
2.6. eNOSActivity inHomogenates of Cardiac andArterial Tis-
sue. The activity of Ca2+/calmodulin-dependent endothelial
nitric oxide synthase, (eNOS) was measured in mesenteric
arteries homogenates and in left ventricle cardiac tissue,
by conversion of L-[3H]arginine into L-[3H]citrulline. Val-
ues were corrected according to protein contents in the
homogenates (Bradford method) and to incubation time and
are expressed as dpm/mg protein/min.Thematerial obtained
from each animal was processed independently [17].
2.7. RelativeHeartWeight. In order to evaluate cardiac hyper-
trophy, we measured relative heart weight (RHW). Briefly,
heart was separated from the great vessels, dropped into a
buffered saline solution (PBS), blotted with tissue paper to
remove blood, and weighed. Total heart weight was corrected
according to the ratio between heart weight (milligrams) and
100 grams of the total body weight before killing.
2.8. Measurement of High-Sensitive C-Reactive Protein (hs-
CRP) Concentration. Plasma hs-CRP concentrations were
measured using a turbidimetric assay (Bayer Advia 1650, AG
Leverkusen). Data are expressed in mg/L.
2.9. Tissue Preservation. Tissue samples for histopathology
were processed as has been previously reported [15]. Samples
from all rats were used for these observations. Anesthetized
animals were briefly perfused with PBS (298 mOsmol/Kg
H
2
O, pH 7.40, 4∘C) to clear out the blood. Mesenteric arteries
were perfused in vivo with the same solution through the
mesenteric artery during 5min. For histological studies,
arteries were also perfused with 4% paraformaldehyde solu-
tion for 10min and fixed by paraffin. Five 𝜇m-thick tissue
slices were transversely cut across the mesenteric tissue on
a microstate (Microm HM, Germany) and processed for
histological studies. Similar procedure was applied for heart
tissue preservation, by aortic retrograde perfusion.
2.10. Quantitative Histomorphometry to Determine Cardiac
Hypertrophy. Histomorphological analyses were conducted
on slices from the outer (free) wall of the left ventricle (LV) of
the heart. Estimations of cardiomyocyte area weremade from
sections stained with Masson trichrome solution. Areas with
transverse sections of myofibers were selected. The contour
of the fibers was then drawn manually. Total myocardiocyte
area was expressed as square micrometer (𝜇m2).
2.11. Arterial Structure. Changes in the structure of arterial
walls were assessed by measuring the media layer in mesen-
teric arteries. Dissected mesenteric vascular beds were fixed
in 10% formaldehyde, dehydrated, embedded in paraffin, and
later cut in microtome.The slices were dyed and examined as
has been previously described [15]. Nontransverse sectioned
arteries were excluded from investigation. The lumen to
media ratio (i.e., internal diameter tomedial thickness) (L/M)
was then calculated. Fifty slices from each animal were
processed and analyzed to obtain an average value for each
rat. Average values were then used for final analysis.
2.12. SDS-PAGE and Immunoblot Analysis. Mesenteric tissue
was washed in PBS and proteins extracted in cold 20mM
Tris-HCl, pH 7.4, 150mM NaCl, 10% glycerol, 1% Triton
X-100, and a protease inhibitor mixture (P2714, Sigma).
After sonication for 15 s (3 times with 10 s intervals) and
extraction for 30min at 4∘C, sample extracts were clarified
by centrifugation at 14,000×g for 20min and used imme-
diately or stored at −20∘C. Proteins were separated on 10%
polyacrylamide slab gels and transferred to 0.22𝜇m nitro-
cellulose membranes (GE, Germany). Nonspecific reactivity
was blocked by incubation for 1 h at room temperature in
5% nonfat dry milk dissolved in washing buffer (PBS, pH
7.6, 0.2% Tween 20). Blots were incubated with anti-p65 and
anti-VCAM-1 antibodies (0.2 𝜇g/mL in blocking solution)
for 60min at room temperature. Horseradish peroxidase-
conjugated goat anti-rabbit-IgG and swine anti-goat-IgG dis-
solved in blocking buffer were used as secondary antibodies
(0.25 𝜇g/mL, 45min at room temperature). Excess first and
second antibodies were removed by washing 5 times for
5min in blocking solution. Detection was accomplished with
enhanced chemiluminescence system (ABC, Dako System)
and subsequent exposure to Kodak X-AR film (Eastman
Kodak) for 5–30 s.
2.13. Immunohistochemistry and Digital Confocal
Microscopy (IHC)
2.13.1. Determination of Transcription Factors (WB). Rabbit
anti-rat NF-𝜅B p65 subunit [Rel A], C-terminus antibody,
was obtained fromMillipore International Inc. (Amsterdam,
The Netherlands) (AB1604b), and goat anti-rat VCAM-1
(C-19) antibody was obtained from Santa Cruz Biotechnol-
ogy Inc. (Santa Cruz, CA, USA) (sc-1504). Tissue sections
were cut at 3 𝜇m thickness from paraffin-embedded blocks.
Deparaffinized sections were used to determine inflamma-
tory response. Tissue was permeabilized in 1% Triton X-100
for 15min, rinsed well with PBS, and blocked with sterile
filtered 10% normal rabbit serum for 20min. All antibody
solutions were microfuged for 20min before use. The anti-
bodieswere 1 : 1000 diluted. Primary incubations lasted 1 hour
at 21-22∘C, followed by extensive washes in PBS with Triton
X-100, six times for 5min each. Secondary antibodies, anti-
rabbit IgG TR and anti-goat IgG FITC (Sigma-Aldrich), were
diluted in PBS alone in compliance with the manufacturer’s
instructions.
Images were collected withNikon EZ-C1 3.00 software on
aNikonDiaphot TMDmicroscope equipped for fluorescence
with a xenon lamp and filter wheels (Sutter Instruments,
Novato, CA, USA), fluorescent filters (Chroma, Brattleboro,
VT, USA), cooled charge-coupled device camera (Cooke,
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Table 1: The above values correspond to metabolic and cardiovascular variables.
Variables W FFR SHR FFHR FFHR + L
SBP (mmHg) 118 ± 0.8 140 ± 1.8∗ 172 ± 2.0∗∧ 182 ± 1.1∗∧# 165 ± 0.9∗∧†
HOMA (𝜇U/mL insulin ×mmol/L glucose)/22.5 4.22 ± 1.1 11.9 ± 1.3∗ 8.1 ± 2.2∗ 15.1 ± 2.5∗ 13.2 ± 2.1∗
Fast glucemia (mmol/L) 4.0 ± 1.1 6.8 ± 1.3∗ 5.2 ± 1.3∗ 6.92 ± 2.1∗ 6.5 ± 2.1∗
Tryglycerides (mg/dL) 72.5 ± 1.9 109 ± 1.8∗ 115 ± 2.4∗ 149 ± 2.2∗∧# 140.9 ± 2.4∗
Relative heart weight (mg/100 g corporal weight) 229 ± 2.5 302 ± 2.1∗ 425 ± 4.4∗ 475 ± 2.6∗∧# 389 ± 2∗∧†
Vascular NAD(P)H-oxidase activity (cpm/mg) 14.5 ± 3.3 68 ± 1.4∗ 149 ± 2.6∗ 366 ± 12∗∧# 197 ± 2.3∗∧#†
TBARS (mmol/L) 39 ± 3.2 118 ± 5.4∗ 110 ± 3.9∗ 171 ± 2.6∗∧# 101 ± 2.7∗∧#†
Arterial eNOS activity (dpm⋅mgP/min) 82.0 ± 2 62 ± 1.5∗ 81.9 ± 2.6 50.6 ± 1.9∗∧# 71.4 ± 1.1∗∧#†
L/M relationship 13.1 ± 1.4 9.5 ± 1.2∗ 8.9 ± 2.1∗ 7.4 ± 1.2∗# 11.5 ± 1.1∗∧#†
PCRus 1.18 ± 0.1 3.2 ± 0.3∗ 4.5 ± 0.1∗ 6.7 ± 0.2∗∧# 1.1 ± 0.2∗∧#
∗
𝑃 < 0.001 versus WKY; ∧𝑃 < 0.001 versus SHR; #𝑃 < 0.01 versus FFR. †versus FFHR.
Tonawanda, NY, USA), and stepper motor (Intelligent Imag-
ing Innovations, Inc., Denver, CO, USA). Multifluor images
were merged, deconvolved, and renormalized using EZ-C1
3.00Thumbnail software.
2.13.2. Determination of Matrix Metalloproteinases. Anti-
MMP-2 was obtained from Chemicon International Inc.
(MAB3308), and anti-MMP-9 antibody was obtained from
Chemicon (MAB3309). Tissue sections were cut at 5 𝜇m
thickness from paraffin-embedded blocks. Deparaffinized
sections were used to determine inflammatory response.
Tissue was permeabilized in 1% Triton X-100 for 15min,
rinsed well with PBS, and blocked with sterile filtered 10%
normal rabbit serum for 20min. All antibody solutions
were microfuged for 20min before use. The antibodies were
diluted 1 : 500. Primary incubationswere done for 1 hour at 21-
22∘C, followed by extensive washes in PBS with Triton X-100,
generally six times for 5min each. Secondary antibodies, Cy5
and FITC IgG (Sigma-Aldrich), were diluted in PBS alone in
compliance with the manufacturer’s instructions.
Images were collected withNikon EZ-C1 3.00 software on
aNikonDiaphot TMDmicroscope equipped for fluorescence
with a xenon lamp and filter wheels (Sutter Instruments,
Novato, CA, USA), fluorescent filters (Chroma, Brattleboro,
VT, USA), cooled charge-coupled device camera (Cooke,
Tonawanda, NY, USA) and stepper motor (Intelligent Imag-
ing Innovations, Inc., Denver, CO, USA). Multi-fluor images
were merged, deconvolved, and renormalized using EZ-C1
3.00Thumbnail software.
Activity of Matrix Metalloproteinases 9 and 2 (Collagenases).
A sample of mesenteric tissue homogenates is obtained using
50 ug of total protein; subsequently a polyacrylamide gel
co-polymerized with gelatin was used. Composition is as
follows: 2880 uL bidistilled water (BD,milliQ), 800 uL gelatin
10mg/mL (Sigma, USP, etc.) (end conc: 1mg gelatin/mL of
gel), 2160 uL acrylamide/bis 30%, 2160 uL Tris-Cl 1.5M pH
8.8, 80 uL SDS 10% (Sigma), 80 uL of ammonium persulfate
10%, and 6 uL TEMED. A third of the sample buffer was
used based on the total sample volume with proteins.The run
was stopped when the phenol red reached the lower edge of
the gel and was starting to overflow it. Then, the gels were
washed to remove the SDS. The gels were washed in 30–
50mL of Triton X-100 2.5% for 20–30min with continuous
agitation. Incubation in 50mL (per gel) of this solution at
37∘C for 12 h approximately Afterwards the gels were stained
with Coomassie blue R-250 for 12 h. For higher contrast it was
used at a concentration of 0.5% (w/v) instead of 0.1%. Gels
were decolorated with solution of methanol, acetic acid, and
water. Metalloprotease activity was evaluated based on mean
optical density of light bands on a dark blue background.
2.14. Reagents. The drug Lumiracoxib in pure state was
provided by Novartis Basel.
Unless otherwise noted, reagents were purchased from
Sigma Chemical Co, MO, USA.
2.15. Statistical and Data Analysis. Data are expressed as
mean ± SEM. The statistical significance of data comparison
between all groups was assessed by one-way ANOVA fol-
lowed by Bonferroni posttest. A two-sided𝑃 value of less than
0.05 was considered significant.
3. Results
Levels of systolic blood pressure increased gradually through-
out the entire experimental period in animals of groups FFR,
SHR, and FFHR, reaching significant differences with respect
to the control group at the end of the protocol (Table 1).
Chronic treatment with L significantly decreased TA values
in groups FFR, FFHR, and SHR but not to the values of the
control group (Table 1).
Furthermore, FFR and FFHR groups are characterized
as a model of metabolic syndrome according to the increase
of the HOMA index, fasting blood glucose, triglycerides,
decreased HDL-cholesterol, and arterial hypertension. Ani-
mals in the experimental groups FFR and FFHR which
received L did not have significantly modified values of
fasting blood glucose, triglycerides, and HDL-cholesterol
(Table 1).
Oxidative stress variables were evaluated in the four
experimental models. NADPH oxidase activity increased
significantly in all experimental models but did so expo-
nentially in the FFHR model. On the other hand eNOS
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Figure 1: Continued.
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Figure 1: Cytoplasmatic and nuclear p-65 fraction of NF-𝜅B and VCAM-1 expression in mesenteric arteries byWB and IHC. up panel shows
the WB representative membrane and which analyzed anti-VCAM-1-FITC and anti-p65-TRITC, the results were obtained by optic density
of the bands revealed for each group. top panel shows microphotographs obtained by laser ICM 600x of mesenteric tissue.
activity decreased significantly in the experimental models
with fructose feeding (Table 1). Lipid peroxidation was
evaluated from TBARS, which showed significant increases
in all three experimental models, the FFHR model being
the most affected. After chronic treatment with L, aortic
NAD(P)H oxidase activity significantly decreased in groups
FFR, SHR, and FFHR. Endothelial eNOS activity normalized
in the experimental models FFHR and FFR after treatment
with L, and these results were statistically significant.
In addition, cardiac remodeling was evaluated based on
relative cardiac weight (RHW) (Table 1). Experimental mod-
els FFR, SHR, and FFHR showed cardiac remodeling, which
decreased, after chronic treatmentwith L, in the experimental
groups studied but only the FFHR group showed statistically
significance.
Vascular remodeling, as discussed previously, was evalu-
ated based on theM/L ratio. In experimentalmodels FFR, and
FFHR a significant reduction of the media/lumen ratio was
observed, demonstrating the presence of eutrophic remodel-
ing of themesenteric arteries studied. After chronic treatment
with L, we demonstrated an increase of this variable in the
three experimental models, which caused the remodeling
to decrease. It should be noted that this increase in the
remodeling index, although statistically significant, did not
reach normal values, which is an important fact when ana-
lyzing the involvement of COX-2 in the pathophysiological
mechanisms.
After demonstrating the presence of cardiovascular
remodeling in these experimental models, we studied the
presence of inflammatory markers.
At the systemic level, C-reactive protein (hsCRP) was
evaluated; it showed significant differences among FFR and
FFHR models, demonstrating the presence of inflammation
in these groups. After treatment with a COX-2 specific
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Figure 2: A representative polyacrylamide gel for Western blot and zymography for collagenases (MMP-2 and MMP-9). This image showed
activity and expression of collagenases contrasted for each experimental group.The picture below shows the bar graphwith statistical analysis.
antagonist, these variables significantly decreased in the three
experimental models, reaching normal values and demon-
strating the participation of this pathophysiological pathway
in the systemic inflammatory process.
At the vascular level, the expression of these proteins
was assessed by Western blot as shown in Figure 1. In
experimental models FFR, FFHR, and SHR the expression of
these markers increased. After chronic treatment with L, the
translocation of NF-𝜅B to the nucleus and the expression of
VCAM-1 at the cellular membrane level were both reduced in
the experimental models FFR and FFHR (Figure 1).
The expression of the aforementioned markers was stud-
ied by IFI; they were exposed in the vascular wall by laser
colocalization microscopy. The experimental models studied
showed different expression patterns of NF-𝜅B and VCAM-
1. This result was previously reported by our laboratory [18].
Model FFHR presents an important expression of NF-𝜅B in
the entire vascular wall (intima, media, and adventitia) as
well as endothelial expression of VCAM-1, while in other
models both markers were present only in the endothelium.
Treatmentwith L significantly reduced the expression of these
markers, as demonstrated by WB, although inflammation at
the adventitia level was higher in the FFHRmodel (Figure 1).
We also analyzed two markers of vascular remodeling,
MMP-2 and MMP-9.The expression was analyzed usingWB
and the activity by zymography. In models FFR and SHR the
activity and the expression of these MMPs increased moder-
ately, while the FFHR model presents maximum activity and
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Figure 3: Representative figure showing the expression of MMP-2 (blue: Cy5) andMMP-9 (red: TRICT) merge mode in mesenteric arteries.
You can see an increased level of tagging in adventitia for MMP-2 andMMP-9 on experimental models with vascular remodeling: SHR, FFR,
and FFHR. These changes are reversed after administration of L. Microphotographs obtained by laser ICM 600x of mesenteric tissue.
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expression of both collagenases (Figure 2). Chronic treatment
with L significantly reduced the activity and expression of the
MMPs, although in the FFHR model this decrease did not
reach the values of the control group and persisted primarily
at the adventitial level. Figure 2 shows a representative
image of the gels and the statistical analysis. Figure 3 shows
expression by IFI of representative photomicrographs of
these antibodies, with the aim of obtaining a vascular level
location of this expression. MMP-2 andMMP-9 are observed
predominately at the adventitia level.
This finding provides further evidence of the importance
of this vascular layer present in vascular remodeling of
metabolic syndrome.
4. Conclusions
Themost important finding of this study was the demonstra-
tion that ciclioxigenasa-2 participates in the cardiovascular
remodeling associated with metabolic syndrome and the
reversal of this syndrome after chronic treatment with a
specific antagonist, lumiracoxib (L).
We demonstrate that chronic treatment with L did not
modify the metabolic variables associated with metabolic
syndrome of models FFHR and FFR. It partially modified the
oxidative stress variables but reduced total lipid peroxidation
as demonstrated by TBARS, reducing vascular damage and
probably reducing the expression of redox-sensitive genes
such as NF-𝜅B, an important initiator of inflammation.
Both vascular and cardiac remodeling showed significant
differences after treatmentwith L,mainly in the FFHRmodel.
Thiswas also evidenced inmicroscopic sections ofmesenteric
arteries showing less inflammation and decreased expression
of extracellular matrix metalloproteinases.
The initiation of the atherosclerotic process is associated,
according to some authors, with the presence of endothe-
lial dysfunction (as demonstrated in this model) and local
inflammation in a first stage, after activating macrophages
that synthesize IL-6, which interacts with hepatocytes and
initiates the release of acute phase reactants such as CRP. NF-
𝜅B is a redox-sensitive transcription factor of great potency
for initiating and perpetuating the inflammatory response; its
most important transcriptional product at the vascular level
is VCAM-1, amarker both of inflammation and of endothelial
dysfunction according to several authors. The number of
these two molecules increased in the entire vascular wall
in the FFHR model and only in the intima layer in FFR
and SHR models, as if they were intermediate products of
WKY rats and FFHR. Epigeneticsmay explain the differential
expression in this model, as fructose is a hidden genes
demethylation in SHR that culminates, at the vascular level,
showing a completely swollen vessel. Chronic treatment with
L altered the expression of inflammatory molecules in the
models that received fructose, although at amicroscopic level
there remains a residue of inflammation in the adventitia.
The remodeling of the vessels can demonstrate that
collagenases, which perform the work “softening” the matrix,
are present in increased numbers [19]. Although the fact
that they have increased does not imply the presence of
remodeling, for that it should be demonstrated that their
activity has also increased and that is why zymography used.
Both MMP-2 and MMP-9 increased in the models studied.
Chronic treatment with L modified the expression and activ-
ity of MMP-2 and MMP-9, increasing at a microscopic level
the media/lumen ratio and thereby improving the vascular
microenvironment.
Other authors have also shown the involvement of COX-
2 in vascular pathophysiology; Dinarello et al. suggest that
a detrimental action of COX-2 has also been described
in hypertensive patients and represents one mechanism
whereby COX-2 may promote atherosclerosis; also they find
that vascular COX-2 downregulation represents a prominent
mechanism whereby statins may attenuate the develop-
ment of the atherosclerotic process in normocholesterolemic
hypertensive patients [20].
As a final conclusion, cyclooxygenase actively participates
in inflammation process and in the remodeling of the vessels,
being an important factor that in the future will allow us
to use these results to pharmacologically improve these
antagonists so that they can be used in clinical practice as
therapeutic targets or as adjuvants in more complete drug
therapies the way monoclonal antibodies are used now [21].
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